Navigation Links
Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
Date:9/11/2008

EMERYVILLE, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will release its fiscal 2008 fourth quarter and year-end financial results on September 16, 2008.

The Company will also host a call to discuss its financial results. Details for the fiscal year-end call are as follows:

-- Date: Tuesday, September 16, 2008

-- Time: 10:30 a.m. ET, 9:30 a.m. CT, 7:30 a.m. PT

-- Dial-in number: 877-874-1565 U.S. & Canada / 719-325-4822 International

The web cast can be accessed online at: http://investor.shareholder.com/ntii/events.cfm

Telephonic Replay: A playback of the conference call will be available from 1:30 pm (ET) on September 16, 2008 to midnight (ET) on September 23, 2008. Reply number: 888-203-1112 U.S. / 719-457-0820 International Pass code: 2312764

The presentation at the Merriman Curhan Ford Investor Summit will take place on Monday, September 15, 2008 at 10:15 a.m. at the Mark Hopkins InterContinental Hotel in San Francisco. Access to the presentation can be found at: http://investor.shareholder.com/ntii/events.cfm

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
2. Neurobiological Technologies CEO to Retire on December 31, 2008
3. Neurobiological Technologies Reports Third Quarter Financial Results
4. Neurobiological Technologies Sets Date for Third Quarter Financial Results
5. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
6. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
7. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
8. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
9. Neurobiological Technologies Sets Date for Research and Development Day
10. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
11. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 2017 According to a new market research report "In ... Disease), & End User (Molecular Diagnostic Laboratories, Academic and Research Institutions) - Global ... 739.9 Million by 2021 from USD 557.1 Million in 2016, growing at a ... ... MarketsandMarkets Logo ...
(Date:1/18/2017)... ... January 18, 2017 , ... Executive search firm ... its continued commitment to the advancement of the clinical trials segment. Hosted in ... to clinical trial planning and management. , As executive talent specialists in ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... announced that it has submitted a 510(k) to the FDA, requesting clearance of ... patent-pending functional electrical stimulation (FES) technology. , The submission marks a major ...
(Date:1/18/2017)... San Francisco, CA (PRWEB) , ... January 18, ... ... delighted to report the publishing of the latest paper by its Science Editor, ... Medical Microbiology (Nederlands Tijdschrift voor Medische Microbiologie). Dr. Bik joined uBiome in October ...
Breaking Biology Technology:
(Date:12/16/2016)... Dec. 16, 2016 The global wearable medical device market, ... by 2021 from USD 5.31 billion in 2016, at a CAGR ... ... by technological advancements in medical devices, launch of a growing number ... wireless connectivity among healthcare providers, and increasing focus on physical fitness. ...
(Date:12/15/2016)...   WaferGen Bio-systems, Inc. (NASDAQ: ... today that on December 13, 2016, it received a ... Stock Market LLC which acknowledged that, as of December ... stock had been at $1.00 or greater for ten ... Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/15/2016)... Dec. 15, 2016 Advancements in ... health wellness and wellbeing (HWW), and security ... three new passenger vehicles begin to feature ... recognition, heart beat monitoring, brain wave monitoring, ... monitoring, and pulse detection. These will be ...
Breaking Biology News(10 mins):